Altered target enzymes (increased dihydrofolate reductase activity or expression, kinetically altered dihydrofolate reductase, increased 5-aminoimidazole-4-carboxamide ribonucleotide ...

Methotrexate (MTX) is a folate analogue originally synthesised in the 1940s and designed to inhibit dihydrofolate reductase.1 Reduced folate (tetrahydrofolate) is the proximal single carbon donor in ...

The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase ...

Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance ...

After absorption, folates are reduced to the active form (tetrahydrofolic acid) by dihydrofolate reductase, and this active form is stored mainly in the liver. The US has an aggressive policy of ...

It is administered orally. The drug candidate targets AKT, PI3K, dihydrofolate reductase (DHFR) and mTORC1/C2 and is developed based on membrane lipid therapy. It was also under development for the ...

Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance ...

Because of the widespread use of the latter—a generic dihydrofolate reductase inhibitor originally used in cancer therapy—in RA, all patients in the recent study were on background methotrexate.

Request permissions for this article.

1 Laboratory of Molecular Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan 2 Department of Microbiology and Immunology, Tohoku University ...

NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., P.O. Box B, Frederick 21702, Maryland, United States ...